Tempus AI

AI Healthcare Tools AI Research & Education Tools

↳AI Medical Research & Clinical Decision Support

Custom

AI precision medicine platform — genomic profiling, clinical insights, and trial matching for personalized cancer care

Not yet rated

Released 2015

Visit Website

Gallery

4 items

VIDEO

About Tempus AI

Tempus AI (NASDAQ: TEM) is a publicly traded technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. Founded in 2015 in Chicago by Eric Lefkofsky (co-founder of Groupon), Tempus has built one of the world's largest libraries of multimodal clinical and molecular data — over 7 million de-identified patient records — powering AI models that help physicians make real-time, data-driven decisions for personalized cancer care and treatment.

Tempus's core offering is comprehensive genomic profiling across solid tumors, germline genetics, RNA expression, liquid biopsy, and pharmacogenomics — delivered through its CLIA-certified, CAP-accredited laboratory. Its AI platform, Tempus One, provides clinicians with real-time treatment insights, drug response predictions, and relevant literature at the point of care. The TIME Trial platform uses AI to match patients to clinical trials based on molecular and clinical profiles, while the Algos population health tool enables health systems to analyze outcomes across their patient cohorts. Tempus also powers drug development for major pharma companies through its biopharma data licensing and research partnerships.

Tempus is the right choice for oncologists, health system genomics programs, academic medical centers, and biopharma R&D teams needing enterprise-grade AI-powered precision medicine infrastructure — from initial genomic testing through treatment decision support, clinical trial matching, and outcomes analytics.

Key Features

Comprehensive genomic profiling — solid tumor (xT), germline (xG), RNA (xR), liquid biopsy (xF), and expression (xE) testing
Multimodal data platform with 7M+ de-identified patient records across clinical, molecular, and imaging data
AI-powered clinical trial matching (TIME Trial) to improve enrollment rates and identify eligible patients
Tempus One — AI clinical assistant for real-time treatment insights and literature synthesis at point of care
Neuropsychiatry panel for pharmacogenomics and psychiatric medication response prediction
Cardiology ECG analysis AI for arrhythmia and cardiac condition detection
Biopharma data licensing and drug development partnerships with major pharma companies
Algos platform for population health analytics across health system patient cohorts
CLIA-certified lab with CAP accreditation for clinical-grade genomic report delivery
Publicly traded (NASDAQ: TEM) — founded 2015, 3,800+ employees, $8.79B total raised

Pros

Publicly traded (NASDAQ: TEM) — one of the most credible precision medicine AI companies
7M+ de-identified patient records — one of the world's largest clinical-molecular datasets
Comprehensive genomic testing across 6 test types covering all major oncology applications
Tempus One AI provides real-time clinical insights at the point of care
TIME Trial dramatically improves clinical trial matching and enrollment rates
3,800+ employees and $8.79B total capital raised since founding
Expanding beyond oncology into neuropsychiatry, cardiology, and infectious disease

Cons

Enterprise and institutional pricing — not accessible to individual clinicians or small practices
Focused primarily on oncology and genomics — not a general-purpose clinical AI tool
Genomic test turnaround requires laboratory processing time
Data platform access and licensing requires formal agreements
Some AI insights require institutional genomic data infrastructure to fully leverage

Pricing

Tempus operates multiple revenue streams with different access models.

Clinical genomic tests (xT, xG, xR, xF, xE) are ordered by physicians through the standard laboratory test ordering process. Pricing varies by test type and is typically covered by insurance for oncology patients. Tempus works directly with health systems to integrate ordering into EHR workflows.

Enterprise data platform access, Algos population health analytics, and biopharma research partnerships are priced through custom enterprise licensing agreements. Biopharma companies license Tempus's de-identified patient datasets and analytical services for drug development and clinical trial design.

Tempus is publicly traded on NASDAQ (ticker: TEM) since June 2024. Investor and enterprise partnership inquiries can be directed through tempus.com.

Claim Verified Creator Badge

Are you the founder of Tempus AI? Display this listing's verified badge on your website to show your customers that your product has been vetted and listed on AI Central Resources.

HTML Embed Code

<a href="https://www.aicentralresources.com/tool/tempus-ai" target="_blank" rel="noopener">
  <img src="https://www.aicentralresources.com/badges/featured-badge-dark.svg" alt="Featured on AICentralResources" width="200" height="54" style="border: none;" />
</a>

* Place this HTML snippet in your website's footer, landing page, or press section. This creates a search-friendly backlink directly to your verification page.

Connect with Tempus AI

X (Twitter)LinkedIn

Frequently Asked Questions

Tempus is a publicly traded (NASDAQ: TEM) AI-powered precision medicine company that combines genomic sequencing, clinical data analytics, and machine learning to help physicians make more informed, personalized treatment decisions for patients — particularly in oncology.

Tempus operates one of the world's largest libraries of multimodal clinical and molecular data, with records on over 7 million de-identified patients. This dataset powers its AI models for treatment insights, drug response prediction, and clinical trial matching.

Tempus offers comprehensive genomic profiling through its xT (solid tumor), xG (germline), xR (RNA), xF (liquid biopsy), and xE (expression) tests, plus specialty tests for neuropsychiatry (Tempus neuropsychiatry panel) and cardiology (ECG analysis).

Tempus's TIME Trial platform uses AI to match patients to clinical trials based on their molecular and clinical profile, dramatically improving clinical trial enrollment rates for oncologists and research institutions.

Yes — Tempus went public on NASDAQ under the ticker TEM in June 2024. It is one of the first major precision medicine AI companies to achieve a public listing, with a market capitalization reflecting its $8B+ total capital raised.